Manjari Joshi

Manjari Joshi

Auto-generated profile, based on publicly available information

Manjari Joshi

Division of Infectious Disease, R Adams Cowley Shock Trauma Center, University of Maryland School of Medicine, Baltimore, MD

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 January 2021 in Journal of Bone and Joint Surgery
Verified
Journal Article
Closed access
CLCarol A. Lin
Carol A. Lin
NONathan N. O'HAra
Nathan N. O'HAra
SSSheila Sprague
Sheila Sprague
RORobert V. O'TOole
Robert V. O'TOole
MJManjari Joshi
Manjari Joshi
TIthe PREP-IT Investigators
the PREP-IT Investigators
Background: Prompt administration of antibiotics is a critical component of open fracture treatment. Traditional antibiotic recommendations have been a first-generation cephalosporin for Gustilo Type-I and Type-II open fractures, with the addition of an aminoglycoside for Type-III fractures and penicillin for soil contamination. However, concerns over changing bacterial patterns and the side effects of aminoglycosides have led to interest in other regimens. The purpose of the present study was to describe the adherence to current prophylactic antibiotic guidelines. Methods: We evaluated the antibiotic-prescribing practices of 24 centers in the U.S. and Canada that were participating in 2 randomized controlled trials of skin-preparation solutions for open fractures. A total of 1,234 patients were evaluated. Results: All patients received antibiotics on the day of admission. The most commonly prescribed antibiotic regimen was cefazolin monotherapy (53.6%). Among patients with Type-I and Type-II fractures, there was 61.1% compliance with cefazolin monotherapy. In contrast, only 17.2% of patients with Type-III fractures received the recommended cefazolin and aminoglycoside therapy, with an additional 6.7% receiving piperacillin/tazobactam. Conclusions: There is moderate adherence to the traditional antibiotic treatment guidelines for Gustilo Type-I and Type-II fractures and low adherence for Type-III fractures. Given the divergence between current practice patterns and prior recommendations, high-quality studies are needed to determine the most appropriate prophylactic protocol.

1 April 2024 in Journal of Orthopaedic Trauma
Verified
Journal Article
Closed access
MJManjari Joshi
Manjari Joshi
RORobert V. O'TOole
Robert V. O'TOole
ACAnthony R. Carlini
Anthony R. Carlini
JGJoshua L. Gary
Joshua L. Gary
WOWilliam T. Obremskey
William T. Obremskey
MEMetrc
Metrc
OBJECTIVE: To determine whether intrawound vancomycin changes the bacteriology of surgical site infection pathogens and investigate the emergence of antibiotic-resistant pathogens. METHODS: Design: Secondary analysis of phase III, prospective, randomized clinical trial. Setting: Thirty-six US trauma centers. Patient Selection Criteria: Patients who became infected after fixation of tibial plateau or pilon fracture. Outcome Measures and Comparisons: Pathogen types and bacterial susceptibilities as determined from routine clinical culture in the operating room. RESULTS: Seventy-four patients were studied who were 67.5% male with a mean age of 48.6 years. A lower proportion of gram-positive cocci was observed in the vancomycin powder compared with the standard-of-care group (3.7% vs. 8.0%, P = 0.01). Methicillin-resistant Staphylococcus aureus infection incidence was comparable in both the vancomycin powder and the standard-of-care groups, but rates of methicillin-susceptible S. aureus infections were lower in the treatment group (1.4% vs. 4.8%, P = 0.01). The incidence of coagulase-negative Staphylococci and gram-negative rod infections were similar in both groups. There was no significant difference in susceptibilities between groups in rates of vancomycin-resistant enterococcus. CONCLUSIONS: Topical vancomycin powder decreases the likelihood of gram-positive infections consistent with the biologic activity of vancomycin. Fewer methicillin-susceptible S. aureus and coagulase-negative Staphylococci infections were observed in the group treated with vancomycin powder. An effect of vancomycin powder on methicillin-resistant S. aureus infection risk was not detected given the low incidence in both the intrawound vancomycin and the standard-of-care groups. There was no emergence of gram-negative rod infections or increased resistance patterns observed. Use of topical vancomycin powder does not seem to produce infections in these patients with greater antibiotic resistance than would have occurred without its use. LEVEL OF EVIDENCE: Therapeutic Level II. See Instructions for Authors for a complete description of levels of evidence.

1 April 2022 in Bone & Joint Open
Verified
Journal Article
Open access
NONathan N. O'HAra
Nathan N. O'HAra
JCJessica Carullo
Jessica Carullo
MJManjari Joshi
Manjari Joshi
MBMary Banoub
Mary Banoub
KCKimberly C. Claeys
Kimberly C. Claeys
PIPREP-IT Investigators
PREP-IT Investigators
Aims: There is increasing evidence to support the use of topical antibiotics to prevent surgical site infections. Although previous research suggests a minimal nephrotoxic risk with a single dose of vancomycin powder, fracture patients often require multiple procedures and receive additional doses of topical antibiotics. We aimed to determine if cumulative doses of intrawound vancomycin or tobramycin powder for infection prophylaxis increased the risk of drug-induced acute kidney injury (AKI) among fracture patients. Methods: This cohort study was a secondary analysis of single-centre Program of Randomized Trials to Evaluate Pre-operative Antiseptic Skin Solutions in Orthopaedic Trauma (PREP-IT) trial data. We included patients with a surgically treated appendicular fracture. The primary outcome was drug-induced AKI. The odds of AKI per gram of vancomycin or tobramycin powder were calculated using Bayesian regression models, which adjusted for measured confounders and accounted for the interactive effects of vancomycin and tobramycin. Results: Of the 782 included patients (mean age 48 years (SD 20); 59% male), 83% (n = 648) received at least one vancomycin dose (cumulative range 1 to 12 g). Overall, 45% of the sample received at least one tobramycin dose (cumulative range 1.2 to 9.6 g). Drug-induced AKI occurred in ten patients (1.2%). No association was found between the cumulative dose of vancomycin and drug-induced AKI (odds ratio (OR) 1.08 (95% credible interval (CrI) 0.52 to 2.14)). Additional doses of tobramycin were associated with a three-fold increase in the adjusted odds of drug-induced AKI (OR 3.66 (95% CrI 1.71 to 8.49)). Specifically, the risk of drug-induced AKI rose substantially after 4.8 g of tobramycin powder (7.5% (95% CrI 1.0 to 35.3)). Conclusion: Cumulative doses of vancomycin were not associated with an increased risk of drug-induced AKI among fracture patients. While the risk of drug-induced AKI remains less than 4% with three or fewer 1.2 g tobramycin doses, the estimated risk increases substantially to 8% after four cumulative doses. Level of evidence: Therapeutic Level III Cite this article: Bone Jt Open 2022;3(4):284–290.

18 January 2022 in Journal of Bone and Joint Surgery
Verified
Journal Article
Closed access
RNRoman Natoli
Roman Natoli
DMDimitrius P. Marinos
Dimitrius P. Marinos
Ryan MontalvoRyan Montalvo
Ryan Montalvo
YDYasmin Degani
Yasmin Degani
GOGeorge Ochenjele
George Ochenjele
RORobert V. O’tOole
Robert V. O’tOole
Background: Next-generation DNA sequencing (NGS) detects bacteria-specific DNA corresponding to the 16S ribosomal RNA gene and can identify bacterial presence with greater accuracy than traditional culture methods. The clinical relevance of these findings is unknown. The purpose of the present study was to compare the results from bacterial culture and NGS in order to characterize the potential use of NGS in orthopaedic trauma patients. Methods: A prospective cohort study was performed at a single academic, level-I trauma center. Three patient groups were enrolled: (1) patients undergoing surgical treatment of acute closed fractures (presumed to have no bacteria), (2) patients undergoing implant removal at the site of a healed fracture without infection, and (3) patients undergoing a first procedure for the treatment of a fracture nonunion who might or might not have subclinical infection. Surgical site tissue was sent for culture and NGS. The proportions of culture and NGS positivity were compared among the groups. The agreement between culture and NGS results was assessed with use of the Cohen kappa statistic. Results: Bacterial cultures were positive in 9 of 111 surgical sites (110 patients), whereas NGS was positive in 27 of 111 surgical sites (110 patients). Significantly more cases were positive on NGS as compared with culture (24% vs. 8.1%; p = 0.001), primarily in the acute closed fracture group. No difference was found in terms of the percent positivity of NGS when comparing the acute closed fracture, implant removal, and nonunion groups. With respect to bacterial identification, culture and NGS agreed in 73% of cases (κ = 0.051; 95% confidence interval, −0.12 to 0.22) indicating only slight agreement compared with expected chance agreement of 50%. Conclusions: NGS identified bacterial presence more frequently than culture, but with only slight agreement between culture and NGS. It is possible that the increased frequency of bacterial detection with molecular methods is reflective of biofilm presence on metal or colonization with nonpathogenic bacteria, as culture methods have selection pressure posed by restrictive, artificial growth conditions and there are low metabolic activity and replication rates of bacteria in biofilms. Our data suggest that NGS should not currently substitute for or complement conventional culture in orthopaedic trauma cases with low suspicion of infection. Level of Evidence: Diagnostic Level II. See Instructions for Authors for a complete description of levels of evidence.

1 June 2023 in Journal of Orthopaedic Trauma
Verified
Journal Article
Closed access
NZNicolas Bs Zingas
Nicolas Bs Zingas
ZHZachary D. Bs Hannan
Zachary D. Bs Hannan
KHKathleen Healey
Kathleen Healey
NMNatasha S McKibben
Natasha S McKibben
CBCynthia Elaine Burke
Cynthia Elaine Burke
RORobert V. O'TOole
Robert V. O'TOole
Objective: To determine the effectiveness of vancomycin powder in preventing infection after plate and screw fixation of tibial plateau fractures considered at low risk of infection. Design: Retrospective cohort study. Setting: Single, Level I trauma center. Patients/Participants: This study included 459 patients with tibial plateau fractures (OTA/AO 41-B/C) who underwent open reduction and internal fixation from 2006 to 2018 and were considered at low risk of infection based on not meeting the “high risk” definition of the VANCO trial. Intervention: Vancomycin powder administration on wound closure at the time of definitive fixation. Main Outcome Measurements: Deep surgical site infection with at least 1 gram-positive bacteria culture. Results: Vancomycin powder administration was associated with reduction in gram-positive infection from 4% to 0% (odds ratio, 0.12; 95% confidence interval, 0.04–0.32; P < 0.01). No significant effect was reported in gram-negative only infections, which were observed in 0.3% in the control group, compared with 0.9% in the intervention group (odds ratio, 2.71; 95% confidence interval, 0.11–69; P = 0.54). Methicillin-resistant Staphylococcus aureus was the most common organism isolated in the control group, growing in 9 of 18 infections (50%). Conclusions: Among patients with low-risk tibial plateau fractures, vancomycin powder at the time of definitive fixation showed a reduction in the incidence of gram-positive deep surgical site infection. The observed relative effect was relatively larger than that observed in a previous randomized trial on high-risk fractures. These data might support broadening the indication for use of vancomycin powder to include tibial plateau fractures at low risk of infection. Level of Evidence: Therapeutic Level III. See Instructions for Authors for a complete description of levels of evidence.

1 March 2002 in Surgical Infections
Verified
Journal Article
Closed access
GBGrant V. Bochicchio
Grant V. Bochicchio
MJManjari Joshi
Manjari Joshi
KKKelly Knorr
Kelly Knorr
ECEllis Caplan
Ellis Caplan
TSThomas Scalea
Thomas Scalea
The incidence of community-acquired infections (CA) and how it relates to the incidence of nosocomial infections (NI) in the adult blunt trauma population is unknown. We evaluated this incidence and assessed the impact of age on morbidity and mortality. Prospective data were collected on blunt trauma patients admitted >48 h over a 2-year period. Each patient was screened for infection by an infectious disease specialist. The Centers for Disease Control and Prevention (CDC) guidelines were used to diagnose infection. Of the 2,645 patients admitted, 86% were <65 years of age and 14% were ≥65 years of age. There was not a significant difference in Injury Severity Score (ISS) between the two groups. A total of 201 (8.8%) of the younger patients were diagnosed with CA; of these, 52.2% acquired a NI. Additionally, 65 (17.4%) of the older patients were diagnosed with a CA; of these, 57% acquired a NI. The combination of CA and NI led to the most significant increases in intensive care (ILOS), hospital (HLOS) length of stay, and mortality. Patients with the CA had a significantly greater risk of obtaining an NI in both age groups. The relative risk (RR) of an older patient presenting with a CA was two times greater than in patients <65 years old. The greatest relative risk of mortality (RRM) was demonstrated with the combination of CA and NI, and age. However, once infected with both CA and NI, younger patients had a greater RRM (5.0 vs. 3.9) in the group-specific comparison. CA significantly increases the risk of blunt trauma patients acquiring an NI. The combination of CA and NI led to the most significant increases in HLOS, ILOS, and mortality. Increased age is associated with a significantly higher incidence of CA, ILOS, HLOS, and mortality. Once infected with both CA and NI, younger patients have a greater risk of mortality.